These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 23263527)

  • 1. Butyricicoccus pullicaecorum in inflammatory bowel disease.
    Eeckhaut V; Machiels K; Perrier C; Romero C; Maes S; Flahou B; Steppe M; Haesebrouck F; Sas B; Ducatelle R; Vermeire S; Van Immerseel F
    Gut; 2013 Dec; 62(12):1745-52. PubMed ID: 23263527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced Mucosa-associated Butyricicoccus Activity in Patients with Ulcerative Colitis Correlates with Aberrant Claudin-1 Expression.
    Devriese S; Eeckhaut V; Geirnaert A; Van den Bossche L; Hindryckx P; Van de Wiele T; Van Immerseel F; Ducatelle R; De Vos M; Laukens D
    J Crohns Colitis; 2017 Feb; 11(2):229-236. PubMed ID: 27484096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress towards butyrate-producing pharmabiotics: Butyricicoccus pullicaecorum capsule and efficacy in TNBS models in comparison with therapeutics.
    Eeckhaut V; Ducatelle R; Sas B; Vermeire S; Van Immerseel F
    Gut; 2014 Feb; 63(2):367. PubMed ID: 23766442
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety assessment of the butyrate-producing Butyricicoccus pullicaecorum strain 25-3(T), a potential probiotic for patients with inflammatory bowel disease, based on oral toxicity tests and whole genome sequencing.
    Steppe M; Van Nieuwerburgh F; Vercauteren G; Boyen F; Eeckhaut V; Deforce D; Haesebrouck F; Ducatelle R; Van Immerseel F
    Food Chem Toxicol; 2014 Oct; 72():129-37. PubMed ID: 25007784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Butyricicoccus pullicaecorum gen. nov., sp. nov., an anaerobic, butyrate-producing bacterium isolated from the caecal content of a broiler chicken.
    Eeckhaut V; Van Immerseel F; Teirlynck E; Pasmans F; Fievez V; Snauwaert C; Haesebrouck F; Ducatelle R; Louis P; Vandamme P
    Int J Syst Evol Microbiol; 2008 Dec; 58(Pt 12):2799-802. PubMed ID: 19060061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual differences in response to treatment with butyrate-producing Butyricicoccus pullicaecorum 25-3T studied in an in vitro gut model.
    Geirnaert A; Wang J; Tinck M; Steyaert A; Van den Abbeele P; Eeckhaut V; Vilchez-Vargas R; Falony G; Laukens D; De Vos M; Van Immerseel F; Raes J; Boon N; Van de Wiele T
    FEMS Microbiol Ecol; 2015 Jun; 91(6):. PubMed ID: 25999470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.
    Machiels K; Joossens M; Sabino J; De Preter V; Arijs I; Eeckhaut V; Ballet V; Claes K; Van Immerseel F; Verbeke K; Ferrante M; Verhaegen J; Rutgeerts P; Vermeire S
    Gut; 2014 Aug; 63(8):1275-83. PubMed ID: 24021287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines.
    Zwolinska-Wcislo M; Krzysiek-Maczka G; Ptak-Belowska A; Karczewska E; Pajdo R; Sliwowski Z; Urbanczyk K; Drozdowicz D; Konturek SJ; Pawlik WW; Brzozowski T
    J Physiol Pharmacol; 2011 Jun; 62(3):357-68. PubMed ID: 21893697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis.
    Hansen R; Russell RK; Reiff C; Louis P; McIntosh F; Berry SH; Mukhopadhya I; Bisset WM; Barclay AR; Bishop J; Flynn DM; McGrogan P; Loganathan S; Mahdi G; Flint HJ; El-Omar EM; Hold GL
    Am J Gastroenterol; 2012 Dec; 107(12):1913-22. PubMed ID: 23044767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid.
    Kabeerdoss J; Jayakanthan P; Pugazhendhi S; Ramakrishna BS
    Indian J Med Res; 2015 Jul; 142(1):23-32. PubMed ID: 26261163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls.
    Vigsnæs LK; Brynskov J; Steenholdt C; Wilcks A; Licht TR
    Benef Microbes; 2012 Dec; 3(4):287-97. PubMed ID: 22968374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease.
    Sha S; Xu B; Wang X; Zhang Y; Wang H; Kong X; Zhu H; Wu K
    Diagn Microbiol Infect Dis; 2013 Mar; 75(3):245-51. PubMed ID: 23276768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis.
    Bajer L; Kverka M; Kostovcik M; Macinga P; Dvorak J; Stehlikova Z; Brezina J; Wohl P; Spicak J; Drastich P
    World J Gastroenterol; 2017 Jul; 23(25):4548-4558. PubMed ID: 28740343
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Loganes C; Valencic E; Pin A; Marini E; Martelossi S; Naviglio S; De Leo L; Not T; Monasta L; Tommasini A; Marcuzzi A
    World J Gastroenterol; 2016 Nov; 22(44):9734-9743. PubMed ID: 27956797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Butyricicoccus pullicaecorum, a butyrate producer with probiotic potential, is intrinsically tolerant to stomach and small intestine conditions.
    Geirnaert A; Steyaert A; Eeckhaut V; Debruyne B; Arends JB; Van Immerseel F; Boon N; Van de Wiele T
    Anaerobe; 2014 Dec; 30():70-4. PubMed ID: 25179909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered Fecal Microbiota in Paediatric Inflammatory Bowel Disease.
    Maukonen J; Kolho KL; Paasela M; Honkanen J; Klemetti P; Vaarala O; Saarela M
    J Crohns Colitis; 2015 Dec; 9(12):1088-95. PubMed ID: 26351391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low counts of Faecalibacterium prausnitzii in colitis microbiota.
    Sokol H; Seksik P; Furet JP; Firmesse O; Nion-Larmurier I; Beaugerie L; Cosnes J; Corthier G; Marteau P; Doré J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1183-9. PubMed ID: 19235886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy.
    Merga Y; Campbell BJ; Rhodes JM
    Dig Dis; 2014; 32(4):475-83. PubMed ID: 24969297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal anti-inflammatory activity of hydroalcoholic extracts of Phlomis purpurea L. and Phlomis lychnitis L. in the trinitrobenzenesulphonic acid model of rat colitis.
    Algieri F; Zorrilla P; Rodriguez-Nogales A; Garrido-Mesa N; Bañuelos O; González-Tejero MR; Casares-Porcel M; Molero-Mesa J; Zarzuelo A; Utrilla MP; Rodriguez-Cabezas ME; Galvez J
    J Ethnopharmacol; 2013 Apr; 146(3):750-9. PubMed ID: 23395625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa.
    Zwolinska-Wcislo M; Brzozowski T; Budak A; Kwiecien S; Sliwowski Z; Drozdowicz D; Trojanowska D; Rudnicka-Sosin L; Mach T; Konturek SJ; Pawlik WW
    J Physiol Pharmacol; 2009 Mar; 60(1):107-18. PubMed ID: 19439813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.